Author ORCID Identifier
Date of Award
Spring 5-4-2022
Degree Type
Dissertation
Degree Name
Doctor of Business Administration (DBA)
Department
Business
First Advisor
Dr. Danny Bellenger
Second Advisor
Dr. Wesley Johnston
Third Advisor
Dr. Naveen Donthu
Abstract
The challenge of bringing new drugs to market through discovery and development is nothing short of daunting in the biopharmaceutical industry. The process is very expensive, very risky and carries a high failure rate, however, it is necessary to sustain the biopharmaceutical industry in bringing new medications to market. In fact, much of the recent literature supports the position that the biopharmaceutical industry faces a more difficult task than most industries in the development of new products, given the escalating cost of research and development, the high regulatory hurdles, and a declining success rate in the discovery of new drug compounds. (Lo, 2021) In addition, the expense of drug discovery and development has a direct impact on the price of medications once they reach the market. Improvements in the drug discovery and development process, therefore, are critical to the long-term success of the biopharmaceutical industry and its ability to find new medications to improve the lives of patients. Artificial Intelligence has long been touted as a route to more efficient, less costly, and more predictable outcomes in the drug discovery and development process. Yet, despite the promise of this technology, there has been little evidence to support that drug discovery and development has become more efficient or less expensive in recent years. In addition, the biopharmaceutical industry has not fully embraced or embedded AI as a core strength in bringing new drugs to market, despite its potential to lower costs, time needed, and manpower required to discover new medicines. This research explores perceived value of AI within the industry as contributing factor to the relatively low adoption of this technology. The specific focus in this research is the view that executive biopharmaceutical managers, tasked with the allocation of limited resources, hold regarding the use, value, and applicability of Artificial Intelligence as a tool within drug discovery and development.
DOI
https://doi.org/10.57709/29080507
Recommended Citation
Murray, Scott P., "Management Perceptions of the Value of Artificial Intelligence in Drug Discovery and Development." Dissertation, Georgia State University, 2022.
doi: https://doi.org/10.57709/29080507
File Upload Confirmation
1